SGLT2 inhibitor for geographic atrophy
Treatments studied
Part of Eyes & vision clinical trials.
This study tests an SGLT2 inhibitor (dapagliflozin) as a possible treatment for geographic atrophy, a progressive form of dry age-related macular degeneration that causes vision loss. It is for people who meet specific eye and health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years of age or older.
- You must have a confirmed diagnosis of geographic atrophy (an advanced form of dry age-related macular degeneration) in at least one eye.
- Your best corrected visual acuity in the study eye must be between 20/25 and 20/320.
- You must not have Type 1 or Type 2 diabetes.
- You must not have had prior treatment for geographic atrophy in the study eye (other than dietary supplements).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This trial tests an oral medication called BRX011 for people with geographic atrophy (a form of advanced dry age-related macular degeneration). The goal is to see if it is safe and can help slow vision loss.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This trial tests a daily eye drop (GAL-101) to see if it can slow the growth of geographic atrophy lesions in people with dry age-related macular degeneration (AMD) when the center of the macula is not yet involved.
Hear when a new Retinal Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.